Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions
CONCLUSION: Rates of bladder cancer progression and disseminated BCG complications 5-years after BCG therapy were similar regardless of immunomodulation status. These findings suggest that BCG intravesical therapy can be offered to immunomodulated patients with high-risk NMIBC although theoretical infectious complication risks remain.PMID:37852817 | DOI:10.1016/j.urolonc.2023.09.010 (Source: Urologic Oncology)
Source: Urologic Oncology - October 18, 2023 Category: Urology & Nephrology Authors: Adri M Durant Mouneeb M Choudry Grace Madura Lanyu Mi Kassem S Faraj Mark D Tyson Source Type: research
Clinical stage and grade migration of localized prostate cancer at diagnosis during the past decade
CONCLUSIONS: Our study confirms an enduring shift towards a higher proportion of aggressive PCa at diagnosis, likely influenced by the COVID-19 pandemic. The impact of the 2018 USPSTF PCa screening recommendation on the proportion of aggressive PCa seems restricted and likely affected by the pandemic outbreak. Future investigations should evaluate the long-term effects of the 2018 USPSTF recommendations in the postpandemic setting.PMID:37852818 | DOI:10.1016/j.urolonc.2023.09.012 (Source: Urologic Oncology)
Source: Urologic Oncology - October 18, 2023 Category: Urology & Nephrology Authors: Edoardo Beatrici Dejan K Filipas Benjamin V Stone Muhieddine Labban Zhiyu Qian Stuart R Lipsitz Giovanni Lughezzani Nicol ò M Buffi Alexander P Cole Quoc-Dien Trinh Source Type: research
Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions
CONCLUSION: Rates of bladder cancer progression and disseminated BCG complications 5-years after BCG therapy were similar regardless of immunomodulation status. These findings suggest that BCG intravesical therapy can be offered to immunomodulated patients with high-risk NMIBC although theoretical infectious complication risks remain.PMID:37852817 | DOI:10.1016/j.urolonc.2023.09.010 (Source: Urologic Oncology)
Source: Urologic Oncology - October 18, 2023 Category: Urology & Nephrology Authors: Adri M Durant Mouneeb M Choudry Grace Madura Lanyu Mi Kassem S Faraj Mark D Tyson Source Type: research
Clinical stage and grade migration of localized prostate cancer at diagnosis during the past decade
CONCLUSIONS: Our study confirms an enduring shift towards a higher proportion of aggressive PCa at diagnosis, likely influenced by the COVID-19 pandemic. The impact of the 2018 USPSTF PCa screening recommendation on the proportion of aggressive PCa seems restricted and likely affected by the pandemic outbreak. Future investigations should evaluate the long-term effects of the 2018 USPSTF recommendations in the postpandemic setting.PMID:37852818 | DOI:10.1016/j.urolonc.2023.09.012 (Source: Urologic Oncology)
Source: Urologic Oncology - October 18, 2023 Category: Urology & Nephrology Authors: Edoardo Beatrici Dejan K Filipas Benjamin V Stone Muhieddine Labban Zhiyu Qian Stuart R Lipsitz Giovanni Lughezzani Nicol ò M Buffi Alexander P Cole Quoc-Dien Trinh Source Type: research
Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions
CONCLUSION: Rates of bladder cancer progression and disseminated BCG complications 5-years after BCG therapy were similar regardless of immunomodulation status. These findings suggest that BCG intravesical therapy can be offered to immunomodulated patients with high-risk NMIBC although theoretical infectious complication risks remain.PMID:37852817 | DOI:10.1016/j.urolonc.2023.09.010 (Source: Urologic Oncology)
Source: Urologic Oncology - October 18, 2023 Category: Urology & Nephrology Authors: Adri M Durant Mouneeb M Choudry Grace Madura Lanyu Mi Kassem S Faraj Mark D Tyson Source Type: research
Clinical stage and grade migration of localized prostate cancer at diagnosis during the past decade
CONCLUSIONS: Our study confirms an enduring shift towards a higher proportion of aggressive PCa at diagnosis, likely influenced by the COVID-19 pandemic. The impact of the 2018 USPSTF PCa screening recommendation on the proportion of aggressive PCa seems restricted and likely affected by the pandemic outbreak. Future investigations should evaluate the long-term effects of the 2018 USPSTF recommendations in the postpandemic setting.PMID:37852818 | DOI:10.1016/j.urolonc.2023.09.012 (Source: Urologic Oncology)
Source: Urologic Oncology - October 18, 2023 Category: Urology & Nephrology Authors: Edoardo Beatrici Dejan K Filipas Benjamin V Stone Muhieddine Labban Zhiyu Qian Stuart R Lipsitz Giovanni Lughezzani Nicol ò M Buffi Alexander P Cole Quoc-Dien Trinh Source Type: research
Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis
CONCLUSION: Patients with M1PCa demonstrated characteristic genetic mutations compared to M0PCa, which most often influenced androgen receptor signaling and is associated with worse survival. In addition, we identified distinct genetic mutations between castration sensitive and resistant M1PCa. These findings may be used to further our understanding and management of men with PCa.PMID:37838503 | DOI:10.1016/j.urolonc.2023.09.014 (Source: Urologic Oncology)
Source: Urologic Oncology - October 14, 2023 Category: Urology & Nephrology Authors: Mohammed Al-Toubat Samuel Serrano Ahmed Elshafei Kashyap Koul Allison H Feibus K C Balaji Source Type: research
Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis
CONCLUSION: Patients with M1PCa demonstrated characteristic genetic mutations compared to M0PCa, which most often influenced androgen receptor signaling and is associated with worse survival. In addition, we identified distinct genetic mutations between castration sensitive and resistant M1PCa. These findings may be used to further our understanding and management of men with PCa.PMID:37838503 | DOI:10.1016/j.urolonc.2023.09.014 (Source: Urologic Oncology)
Source: Urologic Oncology - October 14, 2023 Category: Urology & Nephrology Authors: Mohammed Al-Toubat Samuel Serrano Ahmed Elshafei Kashyap Koul Allison H Feibus K C Balaji Source Type: research
Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis
CONCLUSION: Patients with M1PCa demonstrated characteristic genetic mutations compared to M0PCa, which most often influenced androgen receptor signaling and is associated with worse survival. In addition, we identified distinct genetic mutations between castration sensitive and resistant M1PCa. These findings may be used to further our understanding and management of men with PCa.PMID:37838503 | DOI:10.1016/j.urolonc.2023.09.014 (Source: Urologic Oncology)
Source: Urologic Oncology - October 14, 2023 Category: Urology & Nephrology Authors: Mohammed Al-Toubat Samuel Serrano Ahmed Elshafei Kashyap Koul Allison H Feibus K C Balaji Source Type: research
Letter to editor
Urol Oncol. 2023 Oct 12:S1078-1439(23)00325-3. doi: 10.1016/j.urolonc.2023.09.011. Online ahead of print.NO ABSTRACTPMID:37833098 | DOI:10.1016/j.urolonc.2023.09.011 (Source: Urologic Oncology)
Source: Urologic Oncology - October 13, 2023 Category: Urology & Nephrology Authors: Nik B Patel Khurshid R Ghani Source Type: research
A new era in the treatment of urothelial carcinoma
Urol Oncol. 2023 Oct 11:S1078-1439(23)00294-6. doi: 10.1016/j.urolonc.2023.08.020. Online ahead of print.ABSTRACTThe advances in targeted therapies, immunotherapy, and the recent emergence of antibody-drug conjugates (ADCs) herald a potential paradigm shift in treating patients with metastatic urothelial cancer. Yet, there are inherent challenges in utilizing these therapies, including the management of treatment-related toxicities. In this special Urologic Oncology: Seminars and Original Investigations issue, we review the latest developments and discuss insights into future research needs.PMID:37833099 | DOI:10.1016/j.ur...
Source: Urologic Oncology - October 13, 2023 Category: Urology & Nephrology Authors: Bishoy Faltas Source Type: research
Letter to editor
Urol Oncol. 2023 Oct 12:S1078-1439(23)00325-3. doi: 10.1016/j.urolonc.2023.09.011. Online ahead of print.NO ABSTRACTPMID:37833098 | DOI:10.1016/j.urolonc.2023.09.011 (Source: Urologic Oncology)
Source: Urologic Oncology - October 13, 2023 Category: Urology & Nephrology Authors: Nik B Patel Khurshid R Ghani Source Type: research
A new era in the treatment of urothelial carcinoma
Urol Oncol. 2023 Oct 11:S1078-1439(23)00294-6. doi: 10.1016/j.urolonc.2023.08.020. Online ahead of print.ABSTRACTThe advances in targeted therapies, immunotherapy, and the recent emergence of antibody-drug conjugates (ADCs) herald a potential paradigm shift in treating patients with metastatic urothelial cancer. Yet, there are inherent challenges in utilizing these therapies, including the management of treatment-related toxicities. In this special Urologic Oncology: Seminars and Original Investigations issue, we review the latest developments and discuss insights into future research needs.PMID:37833099 | DOI:10.1016/j.ur...
Source: Urologic Oncology - October 13, 2023 Category: Urology & Nephrology Authors: Bishoy Faltas Source Type: research
HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study
CONCLUSIONS: HPV+ aBSCC tends to occur more often in younger patients. As reported in other HPV-associated squamous cell carcinomas, HPV+ aBSCC demonstrates significantly reduced frequencies of inactivating mutations in cell cycle regulatory genes with similar GA in MTOR and PIK3CA pathways. The implication of HPV in the pathogenesis of bladder cancer remains unknown but warrants further exploration and clinical validation.PMID:37821306 | DOI:10.1016/j.urolonc.2023.09.001 (Source: Urologic Oncology)
Source: Urologic Oncology - October 11, 2023 Category: Urology & Nephrology Authors: G H Ghelani M Bou Zerdan J Jacob P E Spiess R Li A Necchi P Grivas A Kamat N Danziger D Lin R Huang B Decker E S Sokol L Cheng D Pavlick J S Ross G Bratslavsky A Basnet Source Type: research
HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study
CONCLUSIONS: HPV+ aBSCC tends to occur more often in younger patients. As reported in other HPV-associated squamous cell carcinomas, HPV+ aBSCC demonstrates significantly reduced frequencies of inactivating mutations in cell cycle regulatory genes with similar GA in MTOR and PIK3CA pathways. The implication of HPV in the pathogenesis of bladder cancer remains unknown but warrants further exploration and clinical validation.PMID:37821306 | DOI:10.1016/j.urolonc.2023.09.001 (Source: Urologic Oncology)
Source: Urologic Oncology - October 11, 2023 Category: Urology & Nephrology Authors: G H Ghelani M Bou Zerdan J Jacob P E Spiess R Li A Necchi P Grivas A Kamat N Danziger D Lin R Huang B Decker E S Sokol L Cheng D Pavlick J S Ross G Bratslavsky A Basnet Source Type: research
